Although a plethora of medications and therapies now exist for major depression, roughly one in three diagnosed patients ...

Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company ...

A new study published in the Journal of Affective Disorders has found that adults with major depression show specific ...

While not an official condition, this wave of depressive-like symptoms can be overwhelming. Therapists share the red flags ...

A generative AI–powered therapy chatbot is linked to significant reductions in symptoms of depression, anxiety, and eating ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

In light of these findings, Axsome has announced plans to initiate a Phase 3 trial focusing exclusively on MDD patients with EDS in 2025. This decision comes after observing clinically meaningful and ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

Discover the 6 types of depression affecting millions of Americans, their causes, warning signs, and effective treatments ...

Everyone experiences occasional ups and downs. However, dramatic mood swings and emotional instability that disrupt relationships, work or school and daily living could signal something more: ...

Neuronetics (STIM) announced that Evernorth Health Services, a wholly owned subsidiary of The Cigna Group, has expanded its coverage of ...